Linaclotide Dose B

Phase 3Small molecule

FForest Laboratories

Linaclotide Dose B is one of 54 small molecule programs targeting Constipation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Irritable Bowel SyndromeActive, not recruiting

Chronic ConstipationActive, not recruiting

Irritable Bowel SyndromePhase 2

Active, not recruiting

Chronic ConstipationPhase 3

Active, not recruiting

Competition

Competitive Landscape

185 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Lialda

Takeda

Phase 3

2 2

Xifaxan

SSalix

Phase 3

10 3

Zofran

Novartis

Phase 3

1 4

Amitiza

SSucampo Pharma Americas, LLC

Phase 3

5 5

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 6

Zarontin

PParkedale

Phase 3

1 7

Mesalazine

Ferring

Phase 3

4 8

Saccharomyces Boulardii

BBiocodex

Phase 3

3 9

Trulance

SSalix

Phase 3

4 10

Linaclotide Dose B

FForest Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Chronic Constipation

NCT07431957

Clinical

Trials by Indication[1]

Chronic constipation3 trials

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Completed·FForest Laboratories·Phase 3·NCT00765882·633 enrolled

"Efficacy and Safety of Linaclotide in Chronic Constipation"

Not yet recruiting·MMd Mehedi Shahriar·Phase 4·NCT07431957·90 enrolled

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Completed·FForest Laboratories·Phase 3·NCT01642914·487 enrolled

Irritable Bowel Syndrome2 trials

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Terminated·FForest Laboratories·Phase 2·NCT02559817·101 enrolled

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Completed·FForest Laboratories·Phase 3·NCT00948818·803 enrolled

Constipation1 trial

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Completed·FForest Laboratories·Phase 2·NCT02270983·254 enrolled

NAC1 trial

Effect to Linaclotide on Colonic Motility

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT06989268·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Linaclotide Dose B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Linaclotide Dose B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Linaclotide Dose B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForest Laboratories

Linaclotide Dose B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Chronic constipation3 trials

Irritable Bowel Syndrome2 trials

Constipation1 trial

NAC1 trial

References

Drug Info

Quick Facts

Related News